Market revenue in 2023 | USD 6,190.0 million |
Market revenue in 2030 | USD 18,040.5 million |
Growth rate | 16.5% (CAGR from 2023 to 2030) |
Largest segment | Bioreactors/fermenters |
Fastest growing segment | Cell Culture Products |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioreactors/Fermenters, Cell Culture Products, Filters, Bioreactors Accessories, Bags & Containers |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Corning Inc, Sartorius AG, Eppendorf, Danaher Corp, Boehringer Ingelheim, Getinge AB Class B, Lonza Group Ltd, Avantor Inc, Repligen Corp, Entegris Inc, PBS Biotech, Meissner, Kuhner Shaker |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to upstream bioprocessing market will help companies and investors design strategic landscapes.
Bioreactors/fermenters was the largest segment with a revenue share of 31.04% in 2023. Horizon Databook has segmented the Asia Pacific upstream bioprocessing market based on bioreactors/fermenters, cell culture products, filters, bioreactors accessories, bags & containers covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific is a geographically diverse region with developed and developing economies. Comparatively lower cost of drug manufacturing and development is a key factor that attracts European and North American bioprocessing companies to invest in this region’s market. In addition, affordable labor costs, increasing focus on skilled professionals, and a large patient pool are some of the other factors contributing to the region’s fastest growth rate.
In addition to China, which is the top revenue-generating country in the region, developed economies such as New Zealand and Australia offer significant profitable opportunities for market expansion. Clinical trials conducted in Australia are subjected to strict laws and ethical regulations. However, companies can enter into initial clinical trials rapidly.
Major market players are thus rapidly expanding their businesses by establishing facilities across the Asia Pacific. For instance, Sartorius AG (a European company) currently has facilities in Australia, India, Japan, Malaysia, Singapore, and South Korea, as well as three in China.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific upstream bioprocessing market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific upstream bioprocessing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account